Multiple SARS-CoV-2 variants of concern (VOCs) have been emerging and some have been linked to an increase in case numbers globally. However, there is yet a lack of understanding of the molecular basis for the interactions between the human ACE2 (hACE2) receptor and these VOCs. Here we examined several VOCs including Alpha, Beta, and Gamma, and demonstrate that five variants receptor-binding domain (RBD) increased binding affinity for hACE2, and four variants pseudoviruses increased entry into susceptible cells. Crystal structures of hACE2-RBD complexes help identify the key residues facilitating changes in hACE2 binding affinity. Additionally, soluble hACE2 protein efficiently prevent most of the variants pseudoviruses. Our findings provide important molecular information and may help the development of novel therapeutic and prophylactic agents targeting these emerging mutants.
SARS-CoV-2 can infect many domestic animals, including dogs. Herein, we show that dog angiotensin-converting enzyme 2 (dACE2) can bind to the SARS-CoV-2 spike (S) protein receptor binding domain (RBD), and that both pseudotyped and authentic SARS-CoV-2 can infect dACE2-expressing cells. We solved the crystal structure of RBD in complex with dACE2 and found that the total number of contact residues, contact atoms, hydrogen bonds and salt bridges at the binding interface in this complex are slightly fewer than those in the complex of the RBD and human ACE2 (hACE2). This result is consistent with the fact that the binding affinity of RBD to dACE2 is lower than that of hACE2. We further show that a few important mutations in the RBD binding interface play a pivotal role in the binding affinity of RBD to both dACE2 and hACE2. Our work reveals a molecular basis for cross-species transmission and potential animal spread of SARS-CoV-2, and provides new clues to block the potential transmission chains of this virus.
The second wave of the coronavirus disease (COVID-19) pandemic has recently appeared in Europe. Most European countries, such as France, Germany, and Italy, have announced the implementation of a new round of epidemic prevention and control measures. However, no clinical drug or vaccine has been approved for the treatment of COVID-19. The interim results of the solidarity therapy trial coordinated by the World Health Organization (WHO) indicated that remdesivir, hydroxychloroquine, lopinavir/ritonavir, and interferon appear to have little or no effect on the 28-day mortality of hospitalized patients or the hospitalization process of new COVID-19 patients. Therefore, there is an urgent need to develop new drugs against COVID-19. Many viral protease inhibitors, such as telaprevir, asunaprevir, grazoprevir, simeprevir, and darunavir, have been successfully approved for the treatment of HCV and HIV. For coronavirus, the main protease (M pro , 3CL pro) and papain-like protease (PL pro) are responsible for the digestion of viral polyproteins 1a and 1ab to produce 16 active viral nonstructural proteins. These nonstructural
SARS-CoV-2 can infect many domestic animals, including dogs. Herein, we show that dog angiotensin converting enzyme 2 (dACE2) can bind to SARS-CoV-2 spike (S) protein receptor binding region (RBD), and that both pseudotyped and authentic SARS-CoV-2 can infect dACE2-expressing cells. we solved the crystal structure of RBD in complex with dACE2 and found that the total numbers of contact residues, contact atoms, hydrogen bonds and salt bridges at the binding interface in this complex are slightly fewer than those in the complex of the RBD and human ACE2 (hACE2). This result is consistent with the fact that the binding affinity of RBD to dACE2 is lower than that to hACE2. We further show that a few important mutations in the RBD binding interface play a pivotal role in the binding affinity of RBD to both dACE2 and hACE2, and need intense monitoring and controlling.
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has led to more than 5 million deaths worldwide to
date. Due to the limited therapeutic options so far available, target-based virtual
screening with LC/MS support was applied to identify the novel and high-content
compounds
1
–
4
with inhibitory effects on SARS-CoV-2 in
Vero E6 cells from the plant
Dryopteris wallichiana
. These compounds
were also evaluated against SARS-CoV-2 in Calu-3 cells and showed unambiguous inhibitory
activity. The inhibition assay of targets showed that compounds
3
and
4
mainly inhibited SARS-CoV-2 3CLpro, with effective
K
d
values. Through docking and molecular dynamics
modeling, the binding site is described, providing a comprehensive understanding of
3CLpro and interactions for
3
, including hydrogen bonds, hydrophobic bonds,
and the spatial occupation of the B ring. Compounds
3
and
4
represent new, potential lead compounds for the development of anti-SARS-CoV-2 drugs.
This study has led to the development of a target-based virtual screening method for
exploring the potency of natural products and for identifying natural bioactive
compounds for possible COVID-19 treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.